Lung Cancer Resource Center
ALCHEMIST to screen 8,000 patients with early-stage lung cancer, randomly assigning patients with EGFR mutations or rearrangement of the ALK gene.
Oncologists can now provide patients a wide array of treatment options.
Lung Cancer News
Figitumumab Not Safe or Effective for Advanced Non-Adenocarcinoma Non-Small Cell Lung Cancer (NSCLC)
Amrubicin Doesn't Improve Overall Survival vs. Topotecan as Second-Line Treatment for Small-Cell Lung Cancer
Muhammad Rizvi, MD, discusses lung cancer research from ASCO 2014.
More Lung Cancer Information
Patients can learn how to quick smoking cigarettes with the resources found in this informational fact sheet.
This patient fact sheet addresses common questions about the harms of smokeless, chewing tobacco.
This fact sheets answers common questions, risks and health concerns for cigar smoking and cancer.
This fact sheet contains information on the different types of tumors as well as an overview of available biomarker tests.
This slideshow reviews drug information for ZYKADIA™ (ceritinib), indicated for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).
This slideshow reviews Abraxane® (paclitaxel protein-bound particles (albumin-bound) for patients with non-small cell lung cancer.
Table of Contents
Slide 3: Indication, Dosage, ...
By Sandra Cuellar, PharmD, BCOP
A 63-year-old male is referred by his primary care physician for work-up of possible lung cancer. ...
By Tara Morrison, MD; Yu-Ning Wong, MD, MSCE
A 66-year-old African American man presented with a several month history of weight ...
More people in the United States die from lung cancer than any other type of cancer. This is true for ...
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Presenteeism May Be a Problem for Oncologists and, Ultimately, Their Patients
- Mastectomy Rates Rising Among Women with Breast Cancer Eligible for Lumpectomy
- Genetic Diversity May Improve Melanoma Therapy Response
- Figitumumab Not Safe or Effective for Advanced Non-Adenocarcinoma Non-Small Cell Lung Cancer (NSCLC)
- GALNT4 Expression as a Prognostic Indicator in Clear Cell Renal Cell Carcinoma